Startup profile · funding coverage
DeepCell funding, valuation and investors
AI-powered single-cell imaging platform classifying cells by morphology without markers.
Keep track of DeepCell
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$73M · March 2022
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$93M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b
Overview
DeepCell is a Stanford spinout using AI-powered imaging to classify single cells by morphology without markers — 'morpholomics.' a16z participated in a $20M Series A (2020) and re-upped in a $73M Series B (2022) led by Koch Disruptive Technologies. The platform has scaled past 1B labeled cell images.
Why DeepCell is interesting
Stanford spinout using computer vision on intact cells — a16z stayed in through Koch-led Series B as morpholomics atlas scaled past 1B images.
Product & use cases
AI single-cell imaging platform — classify intact cells by morphology without fluorescent markers.
- Label-free cell classification in research
- Morpholomics atlas for cell biology
- High-throughput imaging workflows
Key facts
- Series B (Mar 2022): $73M led by Koch Disruptive Technologies; a16z re-upped (Fierce Biotech)
- Series A (Dec 2020): $20M led by Bow Capital with a16z participation (company press)
- Co-investors not in VCT directory: Koch Disruptive Technologies, Bow Capital, Bridger Healthcare, Horizons Ventures, Casdin Capital
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24
Funding history (newest first)
Series B
2022-03 $73M- Koch Disruptive Technologies (lead)
- Andreessen Horowitz (participant)
Source: https://www.fiercebiotech.com/
Investors in our directory
Funds linked from DeepCell's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: DeepCell differentiates through focused product scope and a16z-backed GTM in its category — see competitors for tradeoffs vs. incumbents.
DeepCell operates in a competitive category where incumbents have distribution but startups win on workflow fit. See named competitors for honest better/worse notes; we do not invent market share.
-
10x Genomics adjacent
Single-cell genomics; DeepCell morphology-focused.
-
Recursion adjacent
AI cell imaging drug discovery at scale.
Notable stories
- Series B (Mar 2022): $73M led by Koch Disruptive Technologies; a16z re-upped (Fierce Biotech)
- Series A (Dec 2020): $20M led by Bow Capital with a16z participation (company press)
Industries
FAQs about DeepCell
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.